The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia.

dc.contributor.author

Lee, Young Mok

dc.contributor.author

Pan, Chi-Jiunn

dc.contributor.author

Koeberl, Dwight D

dc.contributor.author

Mansfield, Brian C

dc.contributor.author

Chou, Janice Y

dc.coverage.spatial

United States

dc.date.accessioned

2015-10-30T14:33:18Z

dc.date.issued

2013-11

dc.description.abstract

Glycogen storage disease type-Ia (GSD-Ia) patients deficient in glucose-6-phosphatase-α (G6Pase-α or G6PC) manifest impaired glucose homeostasis characterized by fasting hypoglycemia, growth retardation, hepatomegaly, nephromegaly, hyperlipidemia, hyperuricemia, and lactic acidemia. Two efficacious recombinant adeno-associated virus pseudotype 2/8 (rAAV8) vectors expressing human G6Pase-α have been independently developed. One is a single-stranded vector containing a 2864-bp of the G6PC promoter/enhancer (rAAV8-GPE) and the other is a double-stranded vector containing a shorter 382-bp minimal G6PC promoter/enhancer (rAAV8-miGPE). To identify the best construct, a direct comparison of the rAAV8-GPE and the rAAV8-miGPE vectors was initiated to determine the best vector to take forward into clinical trials. We show that the rAAV8-GPE vector directed significantly higher levels of hepatic G6Pase-α expression, achieved greater reduction in hepatic glycogen accumulation, and led to a better toleration of fasting in GSD-Ia mice than the rAAV8-miGPE vector. Our results indicated that additional control elements in the rAAV8-GPE vector outweigh the gains from the double-stranded rAAV8-miGPE transduction efficiency, and that the rAAV8-GPE vector is the current choice for clinical translation in human GSD-Ia.

dc.identifier

http://www.ncbi.nlm.nih.gov/pubmed/23856420

dc.identifier

S1096-7192(13)00216-3

dc.identifier.eissn

1096-7206

dc.identifier.uri

https://hdl.handle.net/10161/10803

dc.language

eng

dc.publisher

Elsevier BV

dc.relation.ispartof

Mol Genet Metab

dc.relation.isversionof

10.1016/j.ymgme.2013.06.014

dc.subject

AAV

dc.subject

Adeno-associated virus

dc.subject

G6P

dc.subject

G6PC promoter/enhancer

dc.subject

G6Pase

dc.subject

GPE

dc.subject

GSD-Ia

dc.subject

Gene therapy

dc.subject

Glucose-6-phosphatase

dc.subject

Glycogen storage disease type I

dc.subject

HCA

dc.subject

adeno-associated virus

dc.subject

glucose-6-phosphatase

dc.subject

glucose-6-phosphate

dc.subject

glycogen storage disease type Ia

dc.subject

hepatocellular adenoma

dc.subject

Animals

dc.subject

Dependovirus

dc.subject

Disease Models, Animal

dc.subject

Enhancer Elements, Genetic

dc.subject

Gene Expression

dc.subject

Gene Expression Regulation

dc.subject

Genetic Therapy

dc.subject

Genetic Vectors

dc.subject

Glucose

dc.subject

Glucose-6-Phosphatase

dc.subject

Glycogen Storage Disease Type I

dc.subject

Humans

dc.subject

Liver

dc.subject

Metabolome

dc.subject

Mice

dc.subject

Mice, Knockout

dc.subject

Organ Specificity

dc.subject

Promoter Regions, Genetic

dc.subject

Transduction, Genetic

dc.subject

Transgenes

dc.title

The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia.

dc.type

Journal article

pubs.author-url

http://www.ncbi.nlm.nih.gov/pubmed/23856420

pubs.begin-page

275

pubs.end-page

280

pubs.issue

3

pubs.organisational-group

Basic Science Departments

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Duke

pubs.organisational-group

Molecular Genetics and Microbiology

pubs.organisational-group

Pediatrics

pubs.organisational-group

Pediatrics, Medical Genetics

pubs.organisational-group

School of Medicine

pubs.publication-status

Published

pubs.volume

110

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Preprint Brooks et al 2013 Canine Growth.pdf
Size:
493.18 KB
Format:
Adobe Portable Document Format